NASDAQ:ZYBT

Zhengye Biotechnology Q2 2026 Earnings Results & Report

Zhengye Biotechnology logo
$1.50 -0.02 (-1.32%)
Closing price 04:00 PM Eastern
Extended Trading
$1.48 -0.02 (-1.60%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zhengye Biotechnology reported Q2 2026 earnings on November 12, 2026. The company reported EPS of -$0.03, while revenue was $3.75 million.

Earnings Announcement Details

Quarter
Q2 2026
Time
Before Market Opens

Zhengye Biotechnology EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Zhengye Biotechnology Revenue Results

Actual Revenue
$3.75 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Zhengye Biotechnology Q2 2026 Earnings FAQ

Zhengye Biotechnology (NASDAQ:ZYBT) reported earnings of -$0.03 per share for Q2 2026. The report was announced on Thursday, November 12, 2026.

Zhengye Biotechnology reported revenue of $3.75 million for Q2 2026.

Zhengye Biotechnology Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
Zhengye Biotechnology Holding Ltd (ZYBT)
See More Zhengye Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zhengye Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zhengye Biotechnology and other key companies, straight to your email.

About Zhengye Biotechnology

Zhengye Biotechnology (NASDAQ:ZYBT) is a China-based veterinary biotechnology company that develops, manufactures and sells vaccines and related products for animal health. Its offerings include vaccines used to help prevent infectious diseases in livestock and poultry.

The company serves customers in China’s animal agriculture sector, including producers and veterinary businesses. Its operating history dates to 2004, when its principal operating business was established.

Zhengye also conducts research and development and provides technical support related to its products. Its business focuses on veterinary vaccines rather than medicines for human use.

View Zhengye Biotechnology Profile